ADAG (ADAG) Stock Price & Analysis
ADAG (ADAG) fell 5.04% to USD 3.2 as of July 25, 2026 at 06:44 UTC, according to Nexqual real-time market data.
ADAG last closed at USD 3.37; the session ranged USD 3.17–3.5 on volume of 127,328 shares. Market capitalization is $211.43M, with a 52-week range of USD 1.3–4.85 (NGM). Source: Nexqual, July 25, 2026 at 06:44 UTC.
Key Statistics (as of July 25, 2026 at 06:44 UTC)
| Price | USD 3.2 |
|---|---|
| Change | ▼ 5.04% (down) |
| Previous Close | USD 3.37 |
| Open | USD 3.38 |
| Day Range | USD 3.17 – 3.5 |
| 52-Week Range | USD 1.3 – 4.85 |
| Volume | 127,328 shares |
| Market Cap | $211.43M |
| Exchange | NGM |
Technical Analysis (ADAG)
Nexqual's technical model rates ADAG "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.41 (neutral) |
| vs SMA50 | Below (USD 3.74) |
| MACD | -0.12 (negative) |
Analyst Ratings (ADAG)
Wall Street analysts rate ADAG "Strong Buy" based on 6 analysts, with a mean price target of USD 10.74 (range USD 7–17.45), per Nexqual as of July 25, 2026 at 06:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 10.74 |
| High Target | USD 17.45 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (ADAG)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Financials & Fundamentals (ADAG)
| Total Revenue | $7.67M |
|---|---|
| Revenue Growth (YoY) | +7332.80% |
| Gross Margin | +100.00% |
| Operating Margin | -74.96% |
| Profit Margin | -229.56% |
| ROE | -34.39% |
| Debt / Equity | 12.07 |
| Current Ratio | 3.07 |
| Total Cash | $75.84M |
| Total Debt | $6.26M |
| Free Cash Flow | $-10.25M |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Financial Health Score (ADAG)
Nexqual rates ADAG's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $76M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -34%, ROA -16.0% |
Ownership (ADAG)
| Insider Ownership | +21.61% |
|---|---|
| Institutional Ownership | +12.73% |
| Shares Outstanding | 66.07M |
| Float | 29.51M |
| Short % of Float | +3.90% |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Leadership (ADAG)
ADAG is led by Peter P. Luo (age 59), Co- Founder, Chairman, CEO and President of R & D, per Nexqual as of July 25, 2026 at 06:44 UTC.
| Co- Founder, Chairman, CEO and President of R & D | Peter P. Luo (age 59) |
|---|---|
| CFO & Director | Man Kin Tam (age 48) |
| Executive Director & Head of Human Resources | Ling Zhou |
| Chief Strategy Officer | Mickael Chane-Du |
| Executive Director of Finance | Chunfang Gu |
Major Backers & Investors (ADAG)
Notable institutional backers of ADAG include HSG Holding Ltd, Exome Asset Management LLC , Ameriprise Financial, Inc., according to Nexqual as of July 25, 2026 at 06:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HSG Holding Ltd | 2.83% |
| Exome Asset Management LLC | 1.55% |
| Ameriprise Financial, Inc. | 1.28% |
| Mill Creek Capital Advisors, LLC | 0.42% |
| Invesco | 0.19% |
| Morgan Stanley | 0.14% |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limi | USD 2.14 | ▼ 2.73% |
| ALGS | Aligos Therapeutics, Inc. | USD 4.08 | ▼ 20.78% |
| PHVS | Pharvaris N.V. | USD 34.17 | ▼ 0.55% |
| FTH | Faeth Therapeutics, Inc. | USD 28.29 | ▼ 1.29% |
| ADXN | Addex Therapeutics Ltd | USD 5.89 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:44 UTC. This page is informational and not investment advice.